News for Healthier Living

New Horizons in NSCLC Targeted Therapy: Advancements and Challenges

Recent advances in the treatment of non-small cell lung cancer (NSCLC) have led to improved patient outcomes, particularly for those with actionable gene mutations. Tyrosine kinase inhibitors (TKIs) targeting mutations in genes such as EGFR, ALK, and KRAS have shown effectiveness across various patient groups.

December 11, 2025


December 12 2025

December 11 2025

December 10 2025

December 9 2025

December 8 2025

December 7 2025

December 6 2025

December 5 2025

December 4 2025

December 3 2025

December 2 2025

December 1 2025

November 30 2025

November 29 2025

November 28 2025